CN102357169A - Traditional Chinese medicine composition for treating dysthymia - Google Patents
Traditional Chinese medicine composition for treating dysthymia Download PDFInfo
- Publication number
- CN102357169A CN102357169A CN2011103048884A CN201110304888A CN102357169A CN 102357169 A CN102357169 A CN 102357169A CN 2011103048884 A CN2011103048884 A CN 2011103048884A CN 201110304888 A CN201110304888 A CN 201110304888A CN 102357169 A CN102357169 A CN 102357169A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- radix
- chinese medicine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating dysthymia, belonging to traditional Chinese medicines. The traditional Chinese medicine composition for treating dysthymia is prepared from the following active pharmaceutical ingredients in parts by weight: 27-33 parts of rhizoma cyperi, 8-12 parts of hemlock parsley, 8-12 parts of gardenia, 8-12 parts of rhizoma atractylodis, 27-33 parts of poria with hostwood, 12-18 parts of angelica and 8-12 parts of radix bupleuri. According to the traditional Chinese medicine theoretical formula, the modern pharmacological experimental method sufficiently proves that the traditional Chinese medicine composition for treating dysthymia has the functions of soothing the liver, regulating the flow of qi and relieving the depressed liver, is used for treating dysthymia, and is suitable for patients with depression and stagnation of the liver-qi in traditional Chinese medicine.
Description
Technical field
The invention belongs to Chinese medicine, refer in particular to a kind of Chinese medicine composition of treating dysthymia.
Background technology
Dysthymia; Mental disorder diagnostic and statistical manual in 1994 (the 4th edition) (Diagnostic and Statistic Manual of Mental Disorders-IV; DSM-IV) being interpreted as it with chronic depression property mental state is principal character, and the affective disorder property disease that continues 2 years at least.Dysthymia is many between twenty and fifty onset, shows as depressed, in a depressed state, dejected, anxiety clinically more, and body sense of discomfort and sleep disorder etc. are arranged.China's Epidemiological study data shows that the prevalence of depressive neurosis is 3.02 ‰.Mental sickness high as a kind of prevalence, the serious harm human physical and mental health has caused global extensive concern.(World Health Organization WHO) classifies antidepressants as 21 century and needs most one of medicine of urgent exploitation in World Health Organization (WHO).
Aspect treatment; Treat the main application choice property 5-HT of primary disease reuptake inhibitor (Selective serotonin reuptake inhibitors at present both at home and abroad; SSRIs); (Monoamine oxidase inhibitors MAOIs) waits antidepressant drug and cooperate the psychotherapy to oxidase inhibitor.But because the cause of disease is very not clear and definite as yet, though through systematic treating, curative effect is unsatisfactory, and more side reaction is arranged, like drowsiness, blood pressure reduction, hepatic insufficiency, sexual dysfunction etc.And this condition of disease of Chinese medicine is given full play to that Chinese medicine is efficient, low toxicity and the few advantage of side reaction, is one of development trend of research treatment primary disease.
Summary of the invention
The present invention provides a kind of Chinese medicine composition of treating dysthymia, has depressed liver-energy dispersing and QI regulating, and the function of regulation of mental activities resolving depression is used to treat dysthymia, meets the strongly fragrant sick syndrome of stagnation of liver qi patient of the traditional Chinese medical science.
It is under instruction of Chinese Medicine theory that this medicine is formed, Rhizoma Cyperi acrid in the mouth, little hardship, little sweet in the side, and property is flat, returns Liver Channel, and promoting QI circulation for relieving depression are the Directorate-General DG of disorder of QI, so be we's monarch drug.Meaning in " book on Chinese herbal medicine is looked for the truth ": " Rhizoma Cyperi, the exclusive dissipating depression of QI gas that looses, hardship and not very, resolving depression is in the majority can be added and subtracted discrepancy, think the circulation of qi promoting obstruction-removing prescription ".Radix Bupleuri bitter in the mouth, suffering, cold nature, abnormal smells from the patient are all light, rise and do not fall, and Yang Zhongyin is also.Return liver, gallbladder meridian.Merit with depressed liver-energy dispersing and QI regulating resolving depression, be used with Rhizoma Cyperi, benefit increases the merit of dispersing the stagnated live-QI to relieve the stagnation of QI.The Rhizoma Chuanxiong acrid in the mouth, warm in nature, return liver, gallbladder, pericardium channel.Have invigorate blood circulation, the merit of circulation of qi promoting, pain relieving.The hot temperature of Rhizoma Chuanxiong, on rise up into Liver Channel, the row chong channel, QI regulating medicine also in the blood.With the Radix Bupleuri compatibility, the pain relieving of Rhizoma Chuanxiong blood-activating and qi-promoting, the Radix Bupleuri depressed liver-energy dispersing and QI regulating, two medicines are all gone into Liver Channel, and compatibility is used for the Liver Channel stagnation of QI and the pain in chest and hypochondrium of hematogenous blockage.Because of stagnation of liver-QI then can common dysfunction of the spleen in transportation, thus abide by " seeing the disease of liver, knowing the liver disease will be transmitted into the spleen, tonifying the spleen in the ban " through purport, assistant is with Rhizoma Atractylodis, anti-stagnation of liver-QI restrain criminals spleen soil, invigorating the spleen to clear away damp pathogen is so that it is good for the merit of fortune again.Above compatibility is sayed as Li Shizhen (1518-1593 A.D.): " Rhizoma Cyperi, Rhizoma Chuanxiong, Rhizoma Atractylodis are then always separated Zhu Yu ", so last three medicines are our ministerial drug altogether.For preventing warm-dryness syndrome impairment of YINs such as Rhizoma Cyperi, Radix Bupleuri, so in the qi-activating drug of regulating the flow of vital energy, add Radix Angelicae Sinensis to nourish blood yin fluid astringing, Rhizoma Cyperi, Radix Bupleuri get Radix Angelicae Sinensis to help it, and then hemapodium and strongly fragrant outstanding legibility are also.The Fructus Gardeniae bitter in the mouth, cold in nature, return Liver Channel.Have pathogenic fire purging, heat clearing away, relieving restlessness effect.Its pathogenic fire purging act as the fire in the special eliminating pathogen in the liver, all the other pathogenic fire purgings, must borrow his guiding drug through then rush down also.Poria cum Radix Pini is that Poria is embraced the root survivor, the same Poria of nature and flavor, temperature, sweet in the mouth.Cure mainly slightly same Poria, but that Poria is gone into the usefulness of spleen, kidney is many, Poria cum Radix Pini's spleen invigorating, and it is many to go into the usefulness of the heart, and the merit of mind tranquilizing and the heart calming is arranged is exclusively used in irritability, palpitation with fear, forgetful etc.Over against the vexed card of sleeping less of primary disease, so last three medicines are our adjuvant altogether.
Each amounts of components of medicine of the present invention also is to grope in a large number to sum up through the inventor to draw, each amounts of components better curative effect of tool all in following weight range:
27～33 parts of Rhizoma Cyperis, 8～12 parts of Rhizoma Chuanxiongs, 8～12 parts of Fructus Gardeniaes, 8～12 parts of Rhizoma Atractylodis, 27～33 parts of Poria cum Radix Pinis, 12～18 parts of Radix Angelicae Sinensis, 8～12 parts of Radix Bupleuri.
Be preferably:
30 parts of Rhizoma Cyperis, 10 parts of Rhizoma Chuanxiongs, 10 parts of Fructus Gardeniaes, 10 parts of Rhizoma Atractylodis, 30 parts of Poria cum Radix Pinis, 15 parts of Radix Angelicae Sinensis, 10 parts of Radix Bupleuri.
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations.The method for preparing of preferred medicine activity component of the present invention is following:
One, get it filled material Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri is soaked 1-4h;
Two, get Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis and soak 1-4h;
Three, get soaked Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis, adopt the vapor distillation method to extract the volatile oil in Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Rhizoma Atractylodis, medical material: water ratio is 1: 6-10, and extraction time is 5-8h;
Four, the volatile oil that collect to extract is got medicinal residues such as Rhizoma Cyperi and is carried out reflux, extract, with soaked Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri, extracts 2-3 time, and 1-3h refluxes at every turn;
Five, vacuum concentration medicinal liquid, concentrated solution is dry, surveys relative density 1.30～1.33 during to 50 ℃.
The active component of medicine of the present invention can add various conventional adjuvant required when preparing different dosage form; Like disintegrating agent, lubricant, binding agent etc.; Method of Chinese medicinal with routine is prepared into any peroral dosage form commonly used, like granule, pill, powder, tablet, capsule, oral liquid etc.
Good effect of the present invention is: according to the theory of Chinese medical science prescription, prove fully that through the modern pharmacology experimental technique this medical instrument has depressed liver-energy dispersing and QI regulating, the function of regulation of mental activities resolving depression is used to treat dysthymia, meets the strongly fragrant sick syndrome of stagnation of liver qi patient of the traditional Chinese medical science." dysthymia " belongs to the traditional Chinese medical science " melancholia " category; We treat primary disease and are the principle of the main pathogenesis of primary disease based on " depression of liver-QI "; Be method of treatment with " depressed liver-energy dispersing and QI regulating; regulation of mental activities resolving depression " in the treatment, through clinical observation, objective evaluation gram Yu Shu god exempt to fry in shallow oil the clinical efficacy of electuary treatment syndrome of stagnation of liver qi.Adopt the interior monoamine neurotransmitter of unified dysthymia animal model of disease and morphology and brain, BDNF and mRNA level thereof to study simultaneously as observation index; This medicine is compared with fluoxetine; The curative effect there was no significant difference can improve the depressed behavior of rats with depression, and has illustrated the curative effect mechanism of action of this medicine treatment dysthymia from molecular level; For further Application and Development is laid a good foundation; This inquires into dysthymia morbidity and Chinese medicine mechanism of action for being based on theory of Chinese medical science, and new drug development etc. have big meaning, have a extensive future.Twice of every day is oral, and 6-8g/ time, warm boiled water.
The specific embodiment
The preparation of embodiment 1 tablet of the present invention
Rhizoma Cyperi 27g, Rhizoma Chuanxiong 8g, Fructus Gardeniae 8g, Rhizoma Atractylodis 8g, Poria cum Radix Pini 27g, Radix Angelicae Sinensis 12g, Radix Bupleuri 8g;
One, get it filled material Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri is soaked 1h;
Two, get Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis and soak 1h;
Three, get soaked Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis, adopt the vapor distillation method to extract the volatile oil in Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Rhizoma Atractylodis, medical material: water ratio is 1: 6, and extraction time is 5h;
Four, the volatile oil that collect to extract is got medicinal residues such as Rhizoma Cyperi and is carried out reflux, extract, with soaked Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri, extracts 2 times, and 1h refluxes at every turn;
Five, vacuum concentration medicinal liquid, concentrated solution is dry, surveys relative density 1.30～1.33 during to 50 ℃.
Six, add the conventional adjuvant of preparation tablet, process tablet.
Embodiment 2, the preparation of granule of the present invention
Rhizoma Cyperi 30g, Rhizoma Chuanxiong 10g, Fructus Gardeniae 10g, Rhizoma Atractylodis 10g, Poria cum Radix Pini 30g, Radix Angelicae Sinensis 15g, Radix Bupleuri 10g,
One, get it filled material Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri is soaked 2.5h;
Two, get Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis and soak 2.5h;
Three, get soaked Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis, adopt the vapor distillation method to extract the volatile oil in Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Rhizoma Atractylodis, medical material: water ratio is 1: 8, and extraction time is 6.5h;
Four, the volatile oil that collect to extract is got medicinal residues such as Rhizoma Cyperi and is carried out reflux, extract, with soaked Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri, extracts 3 times, and 2h refluxes at every turn;
Five, vacuum concentration medicinal liquid, concentrated solution is dry, surveys relative density 1.30～1.33 during to 50 ℃.
Six, add starch, medicine and starch proportion are 1: 2, and starch mixes with volatile oil earlier again granulates 60 ℃ of dry 5min with medicament mixed after evenly.
Embodiment 3, the preparation of capsule of the present invention
Rhizoma Cyperi 33g, Rhizoma Chuanxiong 12g, Fructus Gardeniae 12g, Rhizoma Atractylodis 12g, Poria cum Radix Pini 33g, Radix Angelicae Sinensis 18g, Radix Bupleuri 12g;
One, get it filled material Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri is soaked 4h;
Two, get Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis and soak 4h;
Three, get soaked Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis, adopt the vapor distillation method to extract the volatile oil in Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Rhizoma Atractylodis, medical material: water ratio is 1: 10, and extraction time is 8h;
Four, the volatile oil that collect to extract is got medicinal residues such as Rhizoma Cyperi and is carried out reflux, extract, with soaked Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri, extracts 3 times, and 3h refluxes at every turn;
Five, vacuum concentration medicinal liquid, concentrated solution is dry, surveys relative density 1.30～1.33 during to 50 ℃.
Six, the conventional adjuvant that adds the preparation capsule is granulated, and is encapsulated.
Below come further to set forth the beneficial effect of medicine of the present invention through Test Example, these Test Example have comprised the pharmacodynamics test of medicine of the present invention (hereinafter to be referred as the refreshing granule of gram Yu Shu).
This trial drug is an example with the medicine among the embodiment 2.
(1) laboratory animal
Select male Wistar rat for use, body weight is provided by Changchun High-technology Medical Animal Experiment Research Center between 250～300g, (the animal quality certification number be 0017462).Adopt the common rat feed of granular pattern (containing protein 23 %, fat 4.7%, sodium salt 0.24%); Drinking public water supply; Laboratory temperature remains between 17～24 ℃, and periodicity of illumination 12h is to simulate normal day-night rhythm, and the rat special feed is provided by Changchun High-technology Medical Animal Experiment Research Center.
At first do behavioristics scoring with the open-field method, the horizontal movement and the total points that moves both vertically were lower than 30 fens or were higher than 120 minutes animal to be rejected.
(2) grouping and administration
Conform after 1 week, 60 rats are divided into 6 groups at random: dose groups (being called for short " middle dose groups "), the refreshing granule high dose group of gram Yu Shu (being called for short " high dose group ") are each 10 in blank control group, model group, fluoxetine group, the refreshing granule low dose group of gram Yu Shu (being called for short " low dose group "), the refreshing granule of gram Yu Shu.
Blank control group: the same period, the same terms was raised down, arrested and handled under the same terms, and give normal saline 2ml filling stomach every day;
Model group: lonely foster, chronic unpredictalbe mildness stimulates back 1 week beginning to irritate stomach normal saline 2ml every day, and follow procedure applies the modeling stimulation;
Low dose group: stimulate the back to begin to irritate the refreshing granule normal saline solution of stomach gram Yu Shu 2ml 1 week at chronic unpredictalbe mildness, containing the crude drug amount is 6.2g/kg;
Middle dose groups: stimulate the back to begin to irritate the refreshing granule normal saline solution of stomach gram Yu Shu 2ml 1 week at chronic unpredictalbe mildness, containing the crude drug amount is 12.4g/kg;
High dose group: stimulate the back to begin to irritate the refreshing granule normal saline solution of stomach gram Yu Shu 2ml 1 week at chronic unpredictalbe mildness, containing the crude drug amount is 24.8g/kg;
The fluoxetine group: rat chronic stimulates back 1 week beginning fluoxetine normal saline solution, presses 3.3mg/kg and irritates stomach 2ml.
(3) result of study
1, to the influence of rat body weight: can obviously increase rat body weight, with fluoxetine curative effect zero difference relatively.
Table 1 is respectively organized the variation
of rat body weight
Annotate: compare with blank control group,
▲P＜0.05,
▲ ▲P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01; Compare with the fluoxetine group,
●P＜0.05,
● ●P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with low dose group; Compare with middle dose groups,
ZeroP＜0.05,
00P＜0.01, identical below the P value meaning.
Table 1 is the result show: respectively organize rat body weight no significant difference (P＞0.05) before the modeling, during 22d, dysthymia rat model body weight obviously reduces (comparing P＜0.01 with matched group), in conjunction with cosmetic variation, explains that model prepares successfully.When 29d, 36d, refreshing middle and high dose groups of granule of gram Yu Shu and fluoxetine group all can obviously increase rat body weight (comparing P＜0.05, P＜0.01 with model group).
2, to ethological influence: 1. horizontal movement: the refreshing granule of gram Yu Shu can significantly increase rat horizontal anomalous movement score, compares the curative effect zero difference with fluoxetine.2. move both vertically: can increase the rat level that moves both vertically, with fluoxetine curative effect zero difference relatively.
Table 2 respectively organize rat Open-Field judicial act relatively (
times of exercise, inferior/3min)
Table 2 horizontal movement is the result show: 15d begins, and significant change appears in dysthymia rat model Open-Field behavioristics, shows as the horizontal anomalous movement score and significantly reduces (with matched group ratio, P＜0.05, P＜0.01).22d begins, and refreshing each dose groups of granule of gram Yu Shu and fluoxetine group can significantly increase rat horizontal anomalous movement score (comparing P＜0.05, P＜0.01 with model group).
The result that moves both vertically shows table 2: 15d begins, and significant change appears in dysthymia rat model Open-Field behavioristics, shows as vertical activity score and significantly reduces (with matched group ratio, P＜0.05, P＜0.01); Refreshing each dose groups of granule of gram Yu Shu can significantly increase the vertical activity score of rat (comparing P＜0.05, P＜0.01 with model group) with the fluoxetine group.
3, to the influence of dysthymia rat layer and hippocampal tissue pathological change: the neuron number is than the model group showed increased under the light microscopic of 1. treatment group treatment back, and pyknosis and vacuolation phenomenon are few.2. observe with normal group similarly under the Electronic Speculum of treatment group treatment back, and compare obvious improvement before the treatment.
4, to the influence of dysthymia rat hypothalamus monoamine neurotransmitter: the refreshing granule of gram Yu Shu can improve 5-HT and NE content.
Table 3 is respectively organized rat hypothalamus change of monoamine neurotransmitter
Table 3 is the result show: compare with blank control group, the content of NE, DA, 5-HT all obviously reduces (P＜0.01) in the model group rat brain hypothalamus, and difference has remarkable meaning.Rat can make NE content rising (P＜0.05) in the rat model hypothalamus after taking the refreshing granule of gram Yu Shu; After taking refreshing granule of gram Yu Shu and fluoxetine, the content of 5-HT obviously raises (P＜0.01), and the content of DA has rising trend, but does not have significant difference (P＞0.05), and the refreshing granule of gram Yu Shu is compared with fluoxetine has equal pharmacological action, but does not have tangible dose-effect relationship.
5, restrain the influence of the refreshing granule of Yu Shu to dysthymia rat hippocampus BDNF: can obviously increase Hippocampus BDNF content, curative effect and fluoxetine are suitable.
Table 4 is respectively organized the cross section area ratio of BDNF positive neuron in the rat hippocampus and the comparison
of average gray value
The area ratio: model group, fluoxetine group, high dose group, middle dose groups, low dose group and blank control group more all have significance meaning (P＜0.05); 4 kinds of interference method groups and model group are relatively; Low dose group, middle dose groups, high dose group difference have significance meaning (P＜0.05); Fluoxetine group not statistically significant (P＞0.05); Explain that three kinds of dosage of the refreshing granule of gram Yu Shu all can improve the area ratio of positive neuron, and fluoxetine the area that improves positive neuron than aspect do not have effect; Between three kinds of dosage of the refreshing granule of gram Yu Shu relatively, high dose group with in, low dose group difference all has utmost point significance meaning (P＜0.01), not statistically significant between middle dose groups and the low dose group (P＞0.05) explains that the low dose group curative effect is best.
Average gray value: each group compares with blank control group, and difference has utmost point significance meaning (P＜0.05); Each group compares with model group; Low dose group, middle dose groups, high dose group difference have significance meaning (P＜0.05); Fluoxetine group not statistically significant (P＞0.05); Explain that three kinds of dosage of the refreshing granule of gram Yu Shu all can obviously reduce average gray value, and fluoxetine there be not effect aspect the reduction average gray value; Between three kinds of dosage of the refreshing granule of gram Yu Shu relatively, high dose group with in, low dose group difference all has utmost point significance meaning (P＜0.01), not statistically significant between middle dose groups and the low dose group (P＞0.05) explains that the low dose group curative effect is best.
6, restrain of the influence of the refreshing granule of Yu Shu: can raise the BDNFmRNA level to the BDNFmRNA of dysthymia rat cerebral tissue level.
Table 5 is respectively organized the comparison
of the BDNFmRNA of rat cerebral tissue electrophoresis product gray-value variation
Annotate: low dose group, high dose group
◆P＞0.05
Table 5 is the result show, compares with blank control group, and the BDNFmRNA of model group rat cerebral tissue expresses and obviously reduces (P＜0.01); Compare with model group, each is organized the BDNFmRNA of rat cerebral tissue and expresses obviously rising (P＜0.01), and wherein the rising of fluoxetine group is the most obvious, is low dose group and high dose group secondly; But high dose group is compared no significant difference (P＞0.05) with low dose group.Explain that fluoxetine effect aspect the raising BDNFmRNA of rat cerebral tissue is the most remarkable.
7, restrain of the influence of the refreshing granule of Yu Shu: raise the 5-HT1A Receptor mRNA, downward modulation 5-HT2A Receptor mRNA to the 5-HT1A of dysthymia rat cerebral tissue, 5-HT2A, D3, beta receptor mRNA level; Can reduce beta receptor mRNA, D3 Receptor mRNA, the downward modulation degree is higher than the fluoxetine group.
Table 6 is respectively organized rat D
3The comparison of receptor mrna electrophoresis product gray-value variation
Table 6 shows, compares the D of model group rat cerebral tissue with blank control group
3Receptor mRNA obviously raise (P＜0.01); Compare low dose group and the D of high dose group rat cerebral tissue with model group
3Receptor mRNA obviously reduces (P＜0.05 or P＜0.01), and wherein low dose group reduces the most obvious; But the fluoxetine group is compared with model group not have obviously and is improved.Explain that the refreshing granule of gram Yu Shu has good adjusting D
3The receptor mrna effect, and fluoxetine is to D
3The regulating action of receptor mrna is not obvious.
Table 7 is respectively organized the 5-HT of rat cerebral tissue
1AThe comparison of receptor mrna electrophoresis product gray-value variation
Annotate: low dose group is compared with high dose group
◆P＞0.05.
Table 7 shows, compares the 5-HT of model group rat cerebral tissue with blank control group
1AThe receptor mrna level obviously reduces (P＜0.01); Compare with model group, each organizes the 5-HT of rat cerebral tissue
1AReceptor mrna obviously raises (P＜0.05 or P＜0.01), and wherein the fluoxetine group raises the most obvious; And high dose group is compared no significant difference (P＞0.05) with low dose group.Explain that fluoxetine is improving the 5-HT of rat cerebral tissue
1AThe receptor mrna aspect is the most obvious than effect.
Table 8 is respectively organized the 5-HT of rat cerebral tissue
2AThe comparison of receptor mrna electrophoresis product gray-value variation
Annotate: low dose group is compared with high dose group
◆P＞0.05.
Table 8 shows, compares the 5-HT of model group rat cerebral tissue with blank control group
2AMRNA expresses obviously raise (P＜0.01); Compare with model group, each organizes the 5-HT of rat cerebral tissue
2AThe receptor mrna level obviously reduces (P＜0.05 or P＜0.01), and wherein the reduction of fluoxetine group is the most obvious, and low dose group is taken second place, but high dose group is compared there was no significant difference (P＞0.05) with low dose group.Explain that fluoxetine is improving the 5-HT of rat cerebral tissue
2AIt is more remarkable that the mRNA aspect restrains the refreshing granule effect of Yu Shu.
Table 9 is respectively organized the comparison
of the beta receptor mRNA of rat cerebral tissue electrophoresis product gray-value variation
Annotate: compare
with model group
Table 9 shows, compares with blank control group, and plain ability beta receptor mRNA expresses obviously raise (P＜0.01) on the model group rat cerebral tissue kidney; Compare with model group, plain ability beta receptor mRNA expression obviously reduce (P＜0.05 or P＜0.01) on low dose group and the high dose group rat cerebral tissue kidney, and wherein low dose group reduces the most obvious; The fluoxetine group is compared there was no significant difference (P＞0.05) with model group.Explain that the refreshing granule of gram Yu Shu has plain ability beta receptor mRNA horizontal force on the well-tuned rat cerebral tissue kidney.
Claims (3)
1. Chinese medicine composition of treating dysthymia is characterized in that being processed by following bulk drugs:
27 ~ 33 parts of Rhizoma Cyperis, 8 ~ 12 parts of Rhizoma Chuanxiongs, 8 ~ 12 parts of Fructus Gardeniaes, 8 ~ 12 parts of Rhizoma Atractylodis, 27 ~ 33 parts of Poria cum Radix Pinis, 12 ~ 18 parts of Radix Angelicae Sinensis, 8 ~ 12 parts of Radix Bupleuri.
2. a kind of Chinese medicine composition of treating dysthymia as claimed in claim 1 is characterized in that being processed by following bulk drugs:
30 parts of Rhizoma Cyperis, 10 parts of Rhizoma Chuanxiongs, 10 parts of Fructus Gardeniaes, 10 parts of Rhizoma Atractylodis, 30 parts of Poria cum Radix Pinis, 15 parts of Radix Angelicae Sinensis, 10 parts of Radix Bupleuri.
3. a kind of method for preparing of treating the Chinese medicine composition of dysthymia as claimed in claim 1: it is characterized in that comprising the following steps:
One, get it filled material Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri is soaked 1-4h;
Two, get Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis and soak 1-4h;
Three, get soaked Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Atractylodis, adopt the vapor distillation method to extract the volatile oil in Rhizoma Cyperi, Radix Angelicae Sinensis, Rhizoma Chuanxiong, the Rhizoma Atractylodis, medical material: water ratio is 1:6-10, and extraction time is 5-8h;
Four, the volatile oil that collect to extract is got medicinal residues such as Rhizoma Cyperi and is carried out reflux, extract, with soaked Fructus Gardeniae, Poria cum Radix Pini and Radix Bupleuri, extracts 2-3 time, and 1-3h refluxes at every turn;
Five, vacuum concentration medicinal liquid, concentrated solution is dry, surveys relative density 1.30 ~ 1.33 during to 50 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103048884A CN102357169A (en) | 2011-10-10 | 2011-10-10 | Traditional Chinese medicine composition for treating dysthymia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103048884A CN102357169A (en) | 2011-10-10 | 2011-10-10 | Traditional Chinese medicine composition for treating dysthymia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102357169A true CN102357169A (en) | 2012-02-22 |
Family
ID=45582586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103048884A Pending CN102357169A (en) | 2011-10-10 | 2011-10-10 | Traditional Chinese medicine composition for treating dysthymia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102357169A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404044A (en) * | 2018-04-25 | 2018-08-17 | 河南中医药大学 | A kind of compound plant stacte essential oil of Huoxue Jieyu |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724060A (en) * | 2005-07-01 | 2006-01-25 | 成都中医药大学附属医院 | A kind of pharmaceutical composition for the treatment of depression and preparation method thereof |
-
2011
- 2011-10-10 CN CN2011103048884A patent/CN102357169A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1724060A (en) * | 2005-07-01 | 2006-01-25 | 成都中医药大学附属医院 | A kind of pharmaceutical composition for the treatment of depression and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 《中国优秀硕士学位论文》 20100215 江雪 "克郁舒神免煎颗粒剂治疗恶劣心境肝气郁结证的研究" 20，27-28 1-3 第2010年卷, 第2期 * |
| 《国医论坛》 20040630 蒋麟 "越鞠丸用于治疗抑郁症的探讨" 15-16 1-3 第19卷, 第3期 * |
| 江雪: ""克郁舒神免煎颗粒剂治疗恶劣心境肝气郁结证的研究"", 《中国优秀硕士学位论文》 * |
| 蒋麟: ""越鞠丸用于治疗抑郁症的探讨"", 《国医论坛》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404044A (en) * | 2018-04-25 | 2018-08-17 | 河南中医药大学 | A kind of compound plant stacte essential oil of Huoxue Jieyu |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101327297B (en) | Chinese medicine composition for treating insomnia | |
| CN104984315A (en) | Traditional Chinese medicine lavipeditum preparation and preparation method thereof | |
| CN105663607A (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN103520505B (en) | Traditional Chinese medicine preparation for treating neurasthenia and preparation method thereof | |
| CN101822789B (en) | Hypotensor treating essential hypertension | |
| CN104474341B (en) | A kind of pharmaceutical composition for the treatment of hyperkinetic syndrome | |
| CN103182022A (en) | Method for preparing traditional Chinese medicinal potus for preventing and treating subhealth condition | |
| CN115837065B (en) | Traditional Chinese medicine composition and application thereof | |
| CN103705774A (en) | Compound composition with effect of treating depression as well as preparation method and application thereof | |
| CN104248717B (en) | A kind of foot-bath traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN112741890B (en) | Traditional Chinese medicine composition for treating vertigo and preparation method thereof | |
| CN102462787B (en) | Chinese medicine composition for treating hypertension and improving hyperlipidemia and preparation method of Chinese medicine composition | |
| CN104524188A (en) | Medicament for treating vascular dementia and preparation method of medicament | |
| CN102357169A (en) | Traditional Chinese medicine composition for treating dysthymia | |
| CN100450512C (en) | Traditional Chinese medicine neck support for treating cervical spondylosis and preparation method thereof | |
| CN103751711A (en) | Anti-depression traditional Chinese medicinal decoction | |
| CN103495108B (en) | Medicine for treating chronic hypotension and preparation method for medicine | |
| CN105853930A (en) | Traditional Chinese medicine composition for treating depression | |
| CN105213736A (en) | Chinese medicine composition of a kind of fat-reducing and uses thereof | |
| CN104055925A (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy | |
| CN105920409A (en) | Medicinal preparation for treating Alzheimer disease and application of medicinal preparation | |
| CN101084947A (en) | Sedative tea containing semen platycladi and angelica sinensis | |
| CN106177585A (en) | A kind of prevention and the Chinese herbal and crude drugs preparations for the treatment of subhealth state | |
| CN105832885A (en) | Traditional Chinese medicine composition for treating insomnia | |
| CN105168589A (en) | Eye-care traditional Chinese medicine gel preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120222 |